Ali Nael

Dr. Ali Nael


Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2011 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
DGDeliang Guo
Deliang Guo
FRFelicia Reinitz
Felicia Reinitz
MYMary Youssef
Mary Youssef
CHCynthia Hong
Cynthia Hong
DNDavid Nathanson
David Nathanson
PMPaul S. Mischel
Paul S. Mischel
Glioblastoma (GBM) is the most common malignant primary brain tumor of adults and one of the most lethal of all cancers. Epidermal growth factor receptor (EGFR) mutations (EGFRvIII) and phosphoinositide 3-kinase (PI3K) hyperactivation are common in GBM, promoting tumor growth and survival, including through sterol regulatory element-binding protein 1 (SREBP-1)–dependent lipogenesis. The role of cholesterol metabolism in GBM pathogenesis, its association with EGFR/PI3K signaling, and its potential therapeutic targetability are unknown. In our investigation, studies of GBM cell lines, xenograft models, and GBM clinical samples, including those from patients treated with the EGFR tyrosine kinase inhibitor lapatinib, uncovered an EGFRvIII-activated, PI3K/SREBP-1–dependent tumor survival pathway through the low-density lipoprotein receptor (LDLR). Targeting LDLR with the liver X receptor (LXR) agonist GW3965 caused inducible degrader of LDLR (IDOL)–mediated LDLR degradation and increased expression of the ABCA1 cholesterol efflux transporter, potently promoting tumor cell death in an in vivo GBM model. These results show that EGFRvIII can promote tumor survival through PI3K/SREBP-1–dependent upregulation of LDLR and suggest a role for LXR agonists in the treatment of GBM patients. Significance: This study reveals that GBM cells have devised a mechanism to subvert the normal pathways for feedback inhibition of cholesterol homeostasis via EGFRvIII and PI3K-dependent activation of SREBP-1. We show that an LXR agonist causes IDOL-mediated LDLR degradation and increases expression of the ABCA1 cholesterol efflux transporter, potently promoting GBM cell death in vivo. These results suggest a role for LXR agonists in the treatment of GBM patients. Cancer Discovery; 1(5): 442–56. ©2011 AACR. Read the Commentary on this article by Moschetta, p. 381 This article is highlighted in the In This Issue feature, p. 367

1 November 2011 in Cancer Discovery
Verified
Journal Article
Closed access
PDF file
KTKazuhiro Tanaka
Kazuhiro Tanaka
IBIvan Babic
Ivan Babic
DNDavid Nathanson
David Nathanson
DADavid Akhavan
David Akhavan
DGDeliang Guo
Deliang Guo
PMPaul S. Mischel
Paul S. Mischel
Although it is known that mTOR complex 2 (mTORC2) functions upstream of Akt, the role of this protein kinase complex in cancer is not well understood. Through an integrated analysis of cell lines, in vivo models, and clinical samples, we demonstrate that mTORC2 is frequently activated in glioblastoma (GBM), the most common malignant primary brain tumor of adults. We show that the common activating epidermal growth factor receptor (EGFR) mutation (EGFRvIII) stimulates mTORC2 kinase activity, which is partially suppressed by PTEN. mTORC2 signaling promotes GBM growth and survival and activates NF-κB. Importantly, this mTORC2–NF-κB pathway renders GBM cells and tumors resistant to chemotherapy in a manner independent of Akt. These results highlight the critical role of mTORC2 in the pathogenesis of GBM, including through the activation of NF-κB downstream of mutant EGFR, leading to a previously unrecognized function in cancer chemotherapy resistance. These findings suggest that therapeutic strategies targeting mTORC2, alone or in combination with chemotherapy, will be effective in the treatment of cancer. Significance: This study demonstrates that EGFRvIII-activated mTORC2 signaling promotes GBM proliferation, survival, and chemotherapy resistance through Akt-independent activation of NF-κB. These results highlight the role of mTORC2 as an integrator of two canonical signaling networks that are commonly altered in cancer, EGFR/phosphoinositide-3 kinase (PI3K) and NF-κB. These results also validate the importance of mTORC2 as a cancer target and provide new insights into its role in mediating chemotherapy resistance, suggesting new treatment strategies. Cancer Discovery; 1(6); 524–38. ©2011 AACR. Read the Commentary on this article by Wick et al., p. 475 This article is highlighted in the In This Issue feature, p. 457

1 May 2013 in Cancer Discovery
Verified
Journal Article
Closed access
PDF file
DADavid Akhavan
David Akhavan
APAlexandra L. Pourzia
Alexandra L. Pourzia
ANAlex A. Nourian
Alex A. Nourian
KWKevin J. Williams
Kevin J. Williams
DNDavid Nathanson
David Nathanson
PMPaul S. Mischel
Paul S. Mischel
Acquired resistance to tyrosine kinase inhibitors (TKI) represents a major challenge for personalized cancer therapy. Multiple genetic mechanisms of acquired TKI resistance have been identified in several types of human cancer. However, the possibility that cancer cells may also evade treatment by co-opting physiologically regulated receptors has not been addressed. Here, we show the first example of this alternate mechanism in brain tumors by showing that EGF receptor (EGFR)-mutant glioblastomas (GBMs) evade EGFR TKIs by transcriptionally de-repressing platelet-derived growth factor receptor β (PDGFRβ). Mechanistic studies show that EGFRvIII signaling actively suppresses PDGFRβ transcription in an mTORC1- and extracellular signal–regulated kinase-dependent manner. Genetic or pharmacologic inhibition of oncogenic EGFR renders GBMs dependent on the consequently de-repressed PDGFRβ signaling for growth and survival. Importantly, combined inhibition of EGFR and PDGFRβ signaling potently suppresses tumor growth in vivo. These data identify a novel, nongenetic TKI resistance mechanism in brain tumors and provide compelling rationale for combination therapy. Significance: These results provide the first clinical and biologic evidence for receptor tyrosine kinase (RTK) “switching” as a mechanism of resistance to EGFR inhibitors in GBM and provide a molecular explanation of how tumors can become “addicted” to a nonamplified, nonmutated, physiologically regulated RTK to evade targeted treatment. Cancer Discov; 3(5); 534–47. ©2013 AACR. This article is highlighted in the In This Issue feature, p. 471

25 February 2013 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
AIAkio Iwanami
Akio Iwanami
BGBeatrice Gini
Beatrice Gini
CZCiro Zanca
Ciro Zanca
TMTomoo Matsutani
Tomoo Matsutani
AAAlvaro Assuncao
Alvaro Assuncao
PMPaul S. Mischel
Paul S. Mischel
Despite their nearly universal activation of mammalian target of rapamycin (mTOR) signaling, glioblastomas (GBMs) are strikingly resistant to mTOR-targeted therapy. We analyzed GBM cell lines, patient-derived tumor cell cultures, and clinical samples from patients in phase 1 clinical trials, and find that the promyelocytic leukemia (PML) gene mediates resistance to mTOR-targeted therapies. Direct mTOR inhibitors and EGF receptor (EGFR) inhibitors that block downstream mTOR signaling promote nuclear PML expression in GBMs, and genetic overexpression and knockdown approaches demonstrate that PML prevents mTOR and EGFR inhibitor-dependent cell death. Low doses of the PML inhibitor, arsenic trioxide, abrogate PML expression and reverse mTOR kinase inhibitor resistance in vivo, thus markedly inhibiting tumor growth and promoting tumor cell death in mice. These results identify a unique role for PML in mTOR and EGFR inhibitor resistance and provide a strong rationale for a combination therapeutic strategy to overcome it.

1 November 2006 in Investigative Radiology
Verified
Journal Article
Closed access
JVJ Pablo Villablanca
J Pablo Villablanca
KNKambiz Nael
Kambiz Nael
RHReza Habibi
Reza Habibi
ANAli Nael
Ali Nael
GLGerhard Laub
Gerhard Laub
JFJ Paul Finn
J Paul Finn
We sought to prospectively evaluate the image quality and visualization of the intracranial arteries using high spatial resolution contrast-enhanced magnetic resonance angiography (CE-MRA) at 3 T and to perform intraindividual comparison with time-of-flight (TOF) MRA and multislice CT angiography (CTA). Twelve patients (5 men, 7 women, 37–71 years of age) with suspected cerebrovascular disease prospectively underwent MRA and CTA. MRA was performed on a 3 T MR system, including both 3-dimensional (3D) TOF (Voxel dimension: 0.6 × 0.5 × 0.9 mm3 in 5 minutes and 40 seconds) and 3D CE-MRA (voxel dimension: 0.7 × 0.7 × 0.8 mm3 in 20 seconds, using parallel acquisition with an acceleration factor of 4). CTA images were acquired on a 16-slice CT scanner (voxel dimension: 0.35 × 0.35 × 0.8 mm3 in 17 seconds). The image quality and visualization of up to 26 intracranial arterial segments in each study was evaluated by 2 experienced radiologists. The arterial diameter for selective intracranial arteries was measured independently on each of the 3 studies, and statistical analysis and comparative correlation was performed. A total of 312 arterial segments were examined by CE-MRA, TOF-MRA, and CTA. The majority of intracranial arteries (87%) were visualized with diagnostic image quality on CE-MRA with a significant correlation to TOF (R values = 0.84; 95% confidence interval 0.79–0.86, P < 0.0001), and to CTA (R values = 0.74; 95% confidence interavl 0.68–0.78, P < 0.001). The image quality for small intracranial arteries, including the anterior-inferior cerebellar artery, the posterior communicating artery, and the M3 branch of the middle cerebral artery, was significantly lower on CE-MRA compared with TOF and CTA (P < 0.03). There was a significant correlation for the dimensional measurements of arterial diameters at CE-MRA with TOF (r = 0.88, 95% confidence interval 0.81–0.93), and CTA (r = 0.83, 95% confidence interval 0.73–0.90). The described 3 T CE-MRA protocol, spanning from the cervical to the intracranial vessels, visualized and characterized the majority of intracranial arteries with image quality comparable with that obtained using TOF-MRA and CTA. Further clinical studies are required to establish the accuracy of the technique in a broader clinical setting.

6 September 2022 in Oncogenesis
Verified
Journal Article
Open access
PDF file
SWStephanie C. Wu
Stephanie C. Wu
AKAhhyun Kim
Ahhyun Kim
YGYijun Gu
Yijun Gu
DMDaniel I. Martinez
Daniel I. Martinez
LZLoredana Zocchi
Loredana Zocchi
CBClaudia Benavente
Claudia Benavente
Loss-of-function mutations at the retinoblastoma (RB1) gene are associated with increased mortality, metastasis, and poor therapeutic outcome in several cancers, including osteosarcoma. However, the mechanism(s) through which RB1 loss worsens clinical outcome remains understudied. Ubiquitin-like with PHD and Ring Finger domains 1 (UHRF1) has been identified as a critical downstream effector of the RB/E2F signaling pathway that is overexpressed in various cancers. Here, we determined the role and regulatory mechanisms of UHRF1 in rendering osteosarcoma cells more aggressive. Higher UHRF1 expression correlated with malignancy in osteosarcoma cell lines, clinical samples, and genetically engineered mouse models. Gain- and loss-of-function assays revealed that UHRF1 has cell-intrinsic and extrinsic functions promoting cell proliferation, migration, invasion, angiogenesis, and metastasis. UHRF1 overexpression induced angiogenesis by suppressing AMPK activation and Semaphorin 3E (SEMA3E) expression. Further, UHRF1-mediated migration and metastasis resulted, at least in part, through altered expression of extracellular vesicles and their cargo, including urokinase-type plasminogen activator (uPA). Novel osteosarcoma genetically engineered mouse models confirmed that knocking out Uhrf1 considerably decreased metastasis and reversed the poorer survival associated with Rb1 loss. This presents a new mechanistic insight into RB1 loss-associated poor prognosis and novel oncogenic roles of UHRF1 in the regulation of angiogenesis and exosome secretion, both critical for osteosarcoma metastasis. This provides substantial support for targeting UHRF1 or its downstream effectors as novel therapeutic options to improve current treatment for osteosarcoma.